¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ë±¸°¡Å縯´ëÇб³º´¿ø ¸Á¸· : 2020-02-29

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ë±¸°¡Å縯´ëÇб³º´¿ø ¸Á¸· : 2020-02-29
±³À°ÀÏÀÚ : 2020-02-29
±³À°Àå¼Ò : ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ  
±³À°ÁÖÁ¦ : ¸Á¸·
ÁÖÃÖ±â°ü : ´ë±¸°¡Å縯´ëÇб³º´¿ø
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¾È°ú  
´ã´çÀÚ : À̽ÃÀº
¿¬¶ôó : 053-650-4728  
À̸ÞÀÏ : dcmc_ot@naver.com      
±³À°Á¾·ù : ¾È°ú      
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ´ë±¸±¤¿ª½Ã
±³À°½Ã°£ : 6 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 60,000¿ø      
ºñ°í »çÀüµî·Ï- Àü¹®ÀÇ 50,000¿ø, Àü°øÀÇ 40,000¿ø ÇöÀåµî·Ï- Àü¹®ÀÇ 60,000¿ø, Àü°øÀÇ 50,000¿ø °èÁ¹øÈ£ 508-13-827509-5(´ë±¸ÀºÇà, ¹é¹ÎÁÖ)      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 09:20~09:30 Multimodal imaging of type 1,2,3 CNV  Á¤Àοµ(°æ»óÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 09:30~09:40 Clinical application of OCTA in ARMD and its allied disease  ÀÌÁÖ¿ë(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 09:40~09:50 Clinical application of OCTA in DMR and BRVO  ¹Úµ¿È£(°æºÏÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 09:50~10:00 Clinical value of wide FP and FA and ICG  »ç°ø¹Î(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 10:00~10:10 Enface OCT imaging  ¾È¼ºÁØ(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 10:10~10:20 AF imaging in retinal field  À¯½Â¿µ(°æÈñÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 10:20~10:30 Imaging of choroid  ¹Ú¼ºÇ¥(ÇѸ²ÀÇ´ë) 
Åä·Ð 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 10:30~10:45 DIscussion  () 
È޽Ġ02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 10:45~11:05 Break  () 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 11:05~11:15 Classification of various drusen  ±èÀ¯Ã¶(°è¸íÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 11:15~11:25 Dry ARMD treatment, present and emerging  ±èÇö¿õ(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 11:25~11:35 Risk factor of geographic atrophy secondary to ARMD  ÃÖ°æ½Ä(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 11:35~11:45 Update of pachychoroid diseases  ÀÌ¿ø±â(´©³×¾È°úº´¿ø) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 11:45~11:55 Treatment of wet ARMD and PCV, experience and future  °íÇüÁØ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 11:55~12:05 Myopic CNV, treatment and DDX  ½ÅÀçÇÊ(°æºÏÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 12:05~12:15 Mactel type 2 current concept  ¿ÀÀç·É(°í·ÁÀÇ´ë) 
Åä·Ð 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 12:15~12:30 DIscussion  () 
½Ä»ç 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 12:30~13:30 Lunch time  () 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 13:30~14:00 ±è½Ãµ¿ ±³¼ö ¼Ò°³ ¹× Ưº° °­¿¬  ±è½Ãµ¿(´ë±¸°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 14:00~14:10 Lessons from DRCR.net protocol I, S, T  ¼ÛÁöÈÆ(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 14:10~14:20 Brief summary of ongoing DRCR.net protocol U, V, W  À̽¿ì(µ¿±¹ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 14:20~14:30 Anti VEGF in DME  Á¶¿µÁØ(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 14:30~14:40 Steroid role in DME  ÀÌÁ¾Çö(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 14:40~14:50 Managenet of refractory DME and DMR progression in real practice  ÁøÈñ½Â(ÀÎÇÏÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 14:50~15:00 Endophthalmitis after intravitreal injection  ¹Ú¿µÈÆ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 15:00~15:10 Current management of vein occlusion  ³²µ¿Èç(°¡ÃµÀÇ´ë) 
Åä·Ð 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 15:10~15:25 Discussion  () 
È޽Ġ02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 15:25~15:40 Break  () 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 15:40~15:50 Vitrectomy for RRD(case slection, tamponade, etc)  ±èö±¸(±è¾È°úº´¿ø) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 15:50~16:00 Vitrectomy for ERM(good vision caes, inner lamellar hole)  ±èÀ±¿µ(´ë±¸°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 16:00~16:10 Vitrectomy for IOL dislocation(various method)  ±è¼º¼ö(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 16:10~16:20 Vitrectomy for macular hole(conventional/flap, prone, tmponade, etc)  ÀÌÁöÀº(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 16:20~16:30 Vitrectomy for uveitis(what cases, combine treatment, etc)  À¯Çü°ï(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 16:30~16:40 Vitrectomy for DMR(how to improve result, adjuvant, etc)  ±èÁß°ï(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 16:40~16:50 3D surgery(merits and limitation)  ¹Ú±ÔÇü(¼­¿ïÀÇ´ë) 
Åä·Ð 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 16:50~17:05 Discussion  () 
±âŸ 02-29 ´ë±¸°¡Å縯´ëÇб³º´¿ø µ¥·¹»ç°ü 3Ãþ µ¥·¹»çȦ 17:05~17:10 Closing  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ë±¸°¡Å縯´ëÇб³º´¿ø ¸Á¸· : 2020-02-29""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦12ȸ °Ç°­º¸Çè ºòµ¥ÀÌÅÍ ÀÚ·áºÐ¼®À» ÅëÇÑ ³í¹®Ãâ°£ ¿öÅ©¼¥ : 2020-02-29
´ÙÀ½±Û Á¦ 6ȸ Á¶Ç÷¸ð¼¼Æ÷ÀÌ½Ä ¾ÆÄ«µ¥¹Ì: 2020-02-29
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
138 ¼­¿ï Á¦14ȸ ÀÓ»óÀÌ°úÇм¼¹Ì³ª(´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ&´ëÇÑÀÌÇÐȸ °øµ¿ÁÖ°ü) : 2018-08-26 0 654 2018-07-28
137 ¼­¿ï Áß¾Ó´ëÇб³º´¿ø Á¦4ȸ Áß¾Ó´ëÇб³ ¼Ò¾Æû¼Ò³â°ú ¿¬¼ö°­Á : 2018-08-26 0 478 2018-07-28
136 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø 13th Yonsei Foot & Ankle Cadaveric Workshop : 2018-08-26 0 409 2018-07-28
135 °æ±â Á¦59ȸ ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ¼¼¹Ì³ª : 2018-08-26 0 1,844 2018-07-28
134 ¼­¿ï Á¦8ȸ »ï¼º¼­¿ïº´¿ø ¼Ò¾Æû¼Ò³â¼¾ÅÍ ½ÉÆ÷Áö¾ö(ÁÖÁ¦: ÈçÈ÷ ¸¸³ª°Ô µÇ´Â ¼Ò¾Æû¼Ò³â Áúȯ) : 2018-08-26 0 723 2018-07-28
133 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø Á¦9ȸ ¿¬¼¼ÀÇ´ë ¼Ò¾Æ°úÇб³½Ç, ¼Ò¾Æ¾Ë·¹¸£±âÈ£Èí±âÁúȯ ¿¬¼ö°­Á : 2018-08-26 0 395 2018-07-28
132 ¼­¿ï 2018 ´ëÇѼö¸éÇÐȸ ¿öÅ©¼¥ : 2018-08-26 0 482 2018-07-28
131 °æºÏ ´ëÇѼҾưúÇÐȸ ¼Ò¾Æû¼Ò³â°ú ¿Ü·¡¿¡¼­ Àû¿ë °¡´ÉÇÑ ÀÓ»óÁö½Ä : 2018-08-26 0 652 2018-07-28
130 °æ³² ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ 2018 Post Graduate Asthma School (2ÀÏÂ÷) : 2018-08-26 0 1,080 2018-07-28
129 ¼­¿ï Á¦5ȸ ´ëÇÑ°³¿ø³»°úÀÇ»çȸ °¨¿°º´ ¹× ¹é½Å½ÉÆ÷Áö¿ò : 2018-08-26 0 527 2018-07-28
128 ¼­¿ï Á¦15Â÷ °æ±âµµÀÇ»çȸ Çмú´ëȸ : 2018-08-26 0 1,154 2018-07-28
127 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø °³¿øÀǸ¦ À§ÇÑ °í/½½°üÀý Áúȯ : 2018-08-25 0 565 2018-07-28
126 ºÎ»ê ´ëÇÑÈäºÎ¿Ü°úÇÐȸ 2018 ECMO Symposium and Simulation Workshop : 2018-08-25 0 2,513 2018-07-28
125 ´ëÀü 2018³â ´ëÇÑÅëÁõÇÐȸ Áö¹æ¼øȸ ÃÊÀ½ÆÄ ¹× °æ¸·¿Ü³»½Ã°æWorkshop_ÃÊÀ½ÆÄ¿öÅ©¼ó : 2018-08-25 0 629 2018-07-28
124 ´ëÀü Ãæ³²´ëÇб³º´¿ø Ãæ³²´ëÇб³ ½Å°æ¿Ü°ú ȨĿ¹Ö ½ÉÆ÷Áö¿ò : 2018-08-25 0 902 2018-07-28
1401 | 1402 | 1403 | 1404 | 1405 | 1406 | 1407 | 1408 | 1409 | 1410
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷